

Patrick C Mchugh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7497619/publications.pdf>

Version: 2024-02-01

33
papers

710
citations

471371

17
h-index

552653

26
g-index

34
all docs

34
docs citations

34
times ranked

1247
citing authors

#	ARTICLE	IF	CITATIONS
1	High incidence of single nucleotide substitutions in the mitochondrial genome is associated with poor semen parameters in men. <i>Journal of Developmental and Physical Disabilities</i> , 2001, 24, 175-182.	3.6	99
2	Evolution of a maternal immune activation (mIA) model in rats: Early developmental effects. <i>Brain, Behavior, and Immunity</i> , 2019, 75, 48-59.	2.0	66
3	A dopamine transporter polymorphism is a risk factor for borderline personality disorder in depressed patients. <i>Psychological Medicine</i> , 2006, 36, 807-813.	2.7	57
4	The Structure and Function of the Dopamine Transporter and its Role in CNS Diseases. <i>Vitamins and Hormones</i> , 2015, 98, 339-369.	0.7	54
5	Relationships Between Angry-Impulsive Personality Traits and Genetic Polymorphisms of the Dopamine Transporter. <i>Biological Psychiatry</i> , 2009, 66, 717-721.	0.7	35
6	Proteomic analysis of embryonic stem cell-derived neural cells exposed to the antidepressant paroxetine. <i>Journal of Neuroscience Research</i> , 2008, 86, 306-316.	1.3	34
7	Role of carbohydrate response element-binding protein (ChREBP) in generating an aerobic metabolic phenotype and in breast cancer progression. <i>British Journal of Cancer</i> , 2014, 110, 715-723.	2.9	30
8	Effects of different isoforms of apoE on aggregation of the α -synuclein protein implicated in Parkinson's disease. <i>Neuroscience Letters</i> , 2016, 618, 146-151.	1.0	28
9	The presence of both serotonin 1A receptor (HTR1A) and dopamine transporter (DAT1) gene variants increase the risk of borderline personality disorder. <i>Frontiers in Genetics</i> , 2014, 4, 313.	1.1	24
10	Contribution of Individual Histidines to Prion Protein Copper Binding. <i>Biochemistry</i> , 2011, 50, 10781-10791.	1.2	21
11	Proteomic analysis of rat hippocampus exposed to the antidepressant paroxetine. <i>Journal of Psychopharmacology</i> , 2010, 24, 1243-1251.	2.0	20
12	Association of a functional polymorphism in the adrenomedullin gene (ADM) with response to paroxetine. <i>Pharmacogenomics Journal</i> , 2010, 10, 126-133.	0.9	20
13	Cognitive ability in Down syndrome and its relationship to urinary neopterin, a marker of activated cellular immunity. <i>Neuroscience Letters</i> , 2017, 636, 254-257.	1.0	20
14	Molecular analysis of polymerase gamma gene and mitochondrial polymorphism in fertile and subfertile men. <i>Journal of Developmental and Physical Disabilities</i> , 2006, 29, 421-433.	3.6	18
15	Counter-regulation of alpha- and beta-synuclein expression at the transcriptional level. <i>Molecular and Cellular Neurosciences</i> , 2013, 57, 33-41.	1.0	17
16	Memory Decline in Down Syndrome and Its Relationship to iPF2alpha, a Urinary Marker of Oxidative Stress. <i>PLoS ONE</i> , 2014, 9, e97709.	1.1	17
17	Transcriptional Regulation of the Beta-Synuclein 5'-Promoter Metal Response Element by Metal Transcription Factor-1. <i>PLoS ONE</i> , 2011, 6, e17354.	1.1	17
18	Repurposing of Trilast for Potential Neuropathic Pain Treatment by Inhibition of Sepiapterin Reductase in the BH ₄ Pathway. <i>ACS Omega</i> , 2019, 4, 11960-11972.	1.6	15

#	ARTICLE	IF	CITATIONS
19	Polymorphisms of sepiapterin reductase gene alter promoter activity and may influence risk of bipolar disorder. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 330-337.	0.7	14
20	A polymorphism of the GTP-cyclohydrolase I feedback regulator gene alters transcriptional activity and may affect response to SSRI antidepressants. <i>Pharmacogenomics Journal</i> , 2011, 11, 207-213.	0.9	13
21	Prion protein expression alters APP cleavage without interaction with BACE-1. <i>Neurochemistry International</i> , 2012, 61, 672-680.	1.9	12
22	The Development of Translational Biomarkers as a Tool for Improving the Understanding, Diagnosis and Treatment of Chronic Neuropathic Pain. <i>Molecular Neurobiology</i> , 2018, 55, 2420-2430.	1.9	12
23	Activation and repression of prion protein expression by key regions of intron 1. <i>Cellular and Molecular Life Sciences</i> , 2009, 66, 3809-3820.	2.4	11
24	The tetrahydrobiopterin pathway: a novel target for the treatment of depression. <i>Pharmacogenomics</i> , 2011, 12, 1625-1627.	0.6	10
25	The Identification of Blood Biomarkers of Chronic Neuropathic Pain by Comparative Transcriptomics. <i>NeuroMolecular Medicine</i> , 2022, 24, 320-338.	1.8	10
26	Increased Oxidative Stress as a Risk Factor in Chronic Idiopathic Axonal Polyneuropathy. <i>Journal of Molecular Neuroscience</i> , 2018, 66, 547-551.	1.1	7
27	Astragalus and human mesenchymal stem cells promote wound healing by mediating immunomodulatory effects through paracrine signaling. <i>Regenerative Medicine</i> , 2022, 17, 219-232.	0.8	7
28	Research of single mitochondrial nucleotide substitutions in male infertility should consider human mitochondrial haplogroups. <i>Journal of Developmental and Physical Disabilities</i> , 2002, 25, 372-373.	3.6	6
29	Downregulation of <i>Ccnd1</i> and <i>Hes6</i> in rat hippocampus after chronic exposure to the antidepressant paroxetine. <i>Acta Neuropsychiatrica</i> , 2008, 20, 307-313.	1.0	6
30	Nonsynonymous Polymorphism in Guanine Monophosphate Synthetase Is a Risk Factor for Unfavorable Thiopurine Metabolite Ratios in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2606-2612.	0.9	4
31	MicroRNA Quantitation During Dendritic Cell Endocytosis Using Imaging Flow Cytometry: Key Factors and Requirements. <i>Cellular Physiology and Biochemistry</i> , 2018, 51, 793-811.	1.1	3
32	Sphingosine and dihydrosphingosine as biomarkers for multiple sclerosis identified by metabolomic profiling using coupled UPLC-MS. <i>Analytical Methods</i> , 2017, 9, 5929-5934.	1.3	2
33	Tetrahydrobiopterin Pathway may Provide Novel Molecular Targets for Acute and Long Term Efficacy of Mood-Regulating Drugs. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2010, 8, 174-181.	0.2	1